SCHEMBL9522068

SCHEMBL9522068

COC(=O)C(Cc1ccc(O)cc1)N(I)I

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.58
ESR2 Q92731 2/20 0.58
MIF P14174 2/20 0.50
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TSHR P16473 1/20 0.44
LNPEP Q9UIQ6 1/20 0.44
MDM4 O15151 1/20 0.44
MDM2 Q00987 1/20 0.44
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SLC7A5 Q01650 1/20 0.41
NLRP3 Q96P20 1/20 0.41
TAAR1 Q96RJ0 2/20 0.41
SLC6A2 P23975 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9522073 1.00 ESR1 (0.58) ESR1ESR2MIFKMT2ANPSR1
Hydrochloric Acid SCHEMBL9522594 0.98 ESR1 (0.56) ESR1ESR2MIFKMT2ANPSR1
Hydrochloric Acid SCHEMBL9522600 0.98 ESR1 (0.56) ESR1ESR2MIFKMT2ANPSR1
SCHEMBL31409225 0.93 ESR1 (0.51) ESR1ESR2MIFKMT2ANPSR1
Hydrochloric Acid SCHEMBL10531321 0.92 ESR1 (0.50) ESR1ESR2MIFKMT2ANPSR1
SCHEMBL4954934 0.87 ESR1 (0.58) ESR1ESR2MIFKMT2ANPSR1
SCHEMBL23072695 0.85 ESR1 (0.59) ESR1ESR2MIFKMT2ANPSR1
SCHEMBL7273379 0.85 ESR1 (0.59) ESR1ESR2MIFKMT2ANPSR1
Hydrochloric Acid SCHEMBL28049650 0.83 ESR1 (0.56) ESR1ESR2MIFKMT2ANPSR1
Hydrochloric Acid SCHEMBL17360629 0.83 ESR1 (0.56) ESR1ESR2MIFKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115330-A1 RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-04-30 US disclosed
US-20260041799-A1 HYDROLYSIS-RESISTANT HYDROGELS AND METHODS OF TREATMENT USING SAME BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-02-12 US disclosed
US-20250295838-A1 HYDROLYSIS-RESISTANT HYDROGELS AND METHODS OF TREATMENT USING SAME BOSTON SCIENTIFIC SCIMED, INC. (US) 2025-09-25 US disclosed
EP-4573145-A1 IODINE LABELED HYDROGELS AND PRECURSORS THEREOF WITH IMPROVED PROPERTIES Boston Scientific Scimed Inc. (US) 2025-06-25 EP disclosed
EP-4573144-A1 IODINATED CROSSLINKED HYDROGELS AND METHODS OF FORMING THE SAME Boston Scientific Scimed Inc. (US) 2025-06-25 EP disclosed
CN-119731240-A Iodine labeled hydrogels and precursors thereof with improved properties 波士顿科学医学有限公司 2025-03-28 CN disclosed
US-20250059237-A1 METHODS OF FORMING RADIOPAQUE PEPTIDES AND MEDICAL HYDROGELS FORMED THEREFROM BOSTON SCIENTIFIC SCIMED, INC. (US) 2025-02-20 US disclosed
WO-2024040039-A9 IODINATED CROSSLINKED HYDROGELS AND METHODS OF FORMING THE SAME BOSTON SCIENTIFIC SCIMED, INC. (US) 2024-10-17 WO disclosed
US-20240335568-A1 RADIOPAQUE POLYSACCHARIDE HYDROGELS AND METHODS OF MAKING THE SAME BOSTON SCIENTIFIC SCIMED, INC. (US) 2024-10-10 US disclosed
US-20240075190-A1 IODINATED CROSSLINKED HYDROGELS AND METHODS OF FORMING THE SAME BOSTON SCIENTIFIC SCIMED, INC. (US) 2024-03-07 US disclosed
US-20240076266-A1 IODINE LABELED HYDROGELS AND PRECURSORS THEREOF WITH IMPROVED PROPERTIES BOSTON SCIENTIFIC SCIMED, INC. (US) 2024-03-07 US disclosed
WO-2024040039-A1 IODINATED CROSSLINKED HYDROGELS AND METHODS OF FORMING THE SAME BOSTON SCIENTIFIC SCIMED, INC. (US) 2024-02-22 WO disclosed
WO-2024040166-A1 IODINE LABELED HYDROGELS AND PRECURSORS THEREOF WITH IMPROVED PROPERTIES BOSTON SCIENTIFIC SCIMED, INC. (US) 2024-02-22 WO disclosed
US-5273885-A Using a polyiodothyronine analog of a phenyl compound containing a hydroxyl group ortho to an iodine SYNTEX (U.S.A.) INC. (US) 1993-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240076266-A1 IODINE LABELED HYDROGELS AND PRECURSORS THEREOF WITH IMPROVED PROPERTIES TPO, FANCI, IGF1R ESR1 3922/4885ESR2 4305/4885MIF 175/4885
US-20240335568-A1 RADIOPAQUE POLYSACCHARIDE HYDROGELS AND METHODS OF MAKING THE SAME CD44, ALG1, CA13 ESR1 4755/4885ESR2 4661/4885MIF 693/4885
US-20250059237-A1 METHODS OF FORMING RADIOPAQUE PEPTIDES AND MEDICAL HYDROGELS FORMED THEREFROM HDGF, IAPP, QRFPR ESR1 3186/4885ESR2 2292/4885MIF 126/4885
US-20260115330-A1 RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS KLK3, BRDT, BPHL ESR1 923/4885ESR2 1846/4885MIF 321/4885
US-20260041799-A1 HYDROLYSIS-RESISTANT HYDROGELS AND METHODS OF TREATMENT USING SAME PAM, CRYAA, COL1A1 ESR1 3646/4885ESR2 3732/4885MIF 1747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.